NWAM LLC’s Acadia Pharmaceuticals ACAD Stock Holding History

NWAM LLC’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-6,810	Closed	-$217K	–	289
2016 Q3	$217K	Hold	6,810	–	–	0.02%	240
2016 Q2	$221K	Buy	+6,810	New	+$228K	0.09%	207

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

NWAM LLC's ACAD Position: Q4 2016 in Review

NWAM LLC sold out of Acadia Pharmaceuticals (ACAD) in Q4 2016, closing a stake of 6,810 shares — an estimated $217K sold.

NWAM LLC first reported a position in ACAD in Q2 2016 and held it in 2 quarters. The position peaked at $221K in Q2 2016. 225 funds tracked by Wall St. Rank hold ACAD as of Q4 2016.

NWAM LLC reported no remaining Acadia Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
NWAM LLC sold 6,810 Acadia Pharmaceuticals shares in Q4 2016, an estimated $217K.
NWAM LLC first reported a position in Acadia Pharmaceuticals in Q2 2016 and held it in 2 quarters.
NWAM LLC's Acadia Pharmaceuticals position peaked at $221K in Q2 2016.
225 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2016.

Based on NWAM LLC's 13F filing for Q4 2016, filed 2 Feb 2017.